CD226 Antikörper (AA 31-333)

Produktnummer ABIN7873782

Der Kaninchen Polyklonal anti-CD226 Antikörper wird verwendet zum Nachweis von CD226 in Proben von Maus und Ratte. Er wurde validiert für WB, FACS, ELISA und IHC (p).

Kurzübersicht für CD226 Antikörper (AA 31-333) (ABIN7873782)

Target: CD226

Reaktivität: Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CD226 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Flow Cytometry (FACS), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Produktdetails anti-CD226 Antikörper

Bindungsspezifität: AA 31-333

Verwendungszweck: Cd226 Antibody / Dnam-1

Aufreinigung: Antigen affinity purified

Immunogen: Recombinant mouse protein (amino acids E31-L333) was used as the immunogen for the Cd226 antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the Cd226 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: After reconstitution, the Cd226 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Details zu CD226

Target: CD226

Andere Bezeichnung: Cd226

Hintergrund: DNAM 1, also known as CD226, is a receptor expressed by peripheral blood T lymphocytes that is involved in intercellular adhesion, lymphocyte signaling, cytotoxicity and lymphokine secretion mediated by cytotoxic T lymphocytes. DNAM 1 is broadly expressed on T cells, NK cells, platelets, monocytes and a subset of B cells. DNAM-1 is also expressed by a subset of CD3 positive thymocytes. This antibody is reported to inhibit T- and NK cell mediated cytotoxicity against tumour cell targets and to block TNF alpha and IFN gamma secretion by alloantigen-specific T-cells.

UniProt: Q8K4F0

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints